普罗布考辅助治疗高血脂非增殖型糖尿病视网膜病变患者的疗效分析

目的 探讨普罗布考在治疗非增殖型糖尿病视网膜病变合并高血脂患者的临床效果，分析普罗布考的应用价值。方法 选择要求为明确诊断为非增殖型糖尿病视网膜病变且有高血脂的患者，62例患者根据随机抽签原则分为对照组和观察组，对照组26例患者给予降血糖、眼部对症治疗，而观察组36例患者则在降血糖、对症治疗的同时服用普罗布考，用量为3片/次，2次/d。两组均治疗6个月。观察比较两组患者血脂指标、眼底指标和抗氧化指标的改善情况，比较两组疗效。结果 两组均能有效的降低血糖及糖化血红蛋白，与治疗前相比差异显著，具有统计学意义（P<0.05），但两组对比则差异不明显。经过6个月的治疗后，观察组患者的超氧化物歧化酶（SOD）和T总抗氧化能力（AOC）显著上升，而丙二醛（MDA）下降，相对于治疗前差异具有统计学意义（P<0.05）；对照组患者治疗前后的差异较小，氧化应激指标的变化无统计学意义；治疗后两组氧化应激指标差异明显，具有统计学意义（P<0.05）。观察组能够有效的改善眼底情况，有效率高达68.06%，而对照组仅有38.46%，两组比较差异具有统计学意义（P<0.05）。普罗布考对非增殖型糖尿病视网膜病变患者的视力有很明显的提高作用，经过6个月的治疗，观察组有效率为75.00%，明显高于对照组的44.23%，差异具有统计学意义（P<0.05）。观察组患者的血脂改善情况显著，而对照组基本无改变，对比治疗后两组的血脂情况可知，差异具有统计学意义（P<0.05）。结论 良好的控制血脂作用和抗氧化能力是普罗布考作用价值的体现，有利于提高患者的使用体验、治疗效果和满意度。

Efficacy of probucol for patients with high blood lipid and non proliferative diabetic retinopathy

Objective To investigate the clinical effect of the probucol for patients with high blood lipid and non proliferative diabetic retinopathy.Methods 62 patients were selected,26 cases were symptomatic treatment,and the remaining 36 cases patients were taking probucol at the same time,the above patients were divided into routine group and drug group.Observed the improvement of systemic symptoms and ocular symptoms in each group.Results Systemic symptoms of patients in the drug group improved significantly,malondialdehyde decreased were significantly higher than those in the routine group,the rise in drug group patients with antioxidant indexes were significantly better than the routine group (P< 0.05).For the eye index after probucol therapy in patients,effectively improved the vision at the same time,could effectively change the fundus and retinal lesions,promoted the average distribution of retinal blood vessels,improved visual function,reduce macular edema,compared with normal group,the differences were statistically significant (P< 0.05).Conclusion Probucol can reduce high blood lipid and Ocular fundus diseases caused by diabetes treatment.